Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

Dupilumab inhibits IL-4 and IL-13, which have been linked to internal tumorigenesis. Perspective from Raj Chovatiya, MD, PhD. Patients who used dupilumab for atopic dermatitis had significantly ...

By blocking the IL-4R alpha subunit, dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E. Scope of ...

USA: A recent case report published in The Open Dermatology Journal has brought attention to the successful use of ...

Dupilumab, a fully human monoclonal antibody, works by inhibiting the signaling of the interleukin 4 (IL-4) and IL-13 pathways and is approved for many conditions characterized by type 2 ...

Dupilumab (Dupixent) is the first new treatment for chronic spontaneous urticaria in over a decade. ... (IL-4) and interleukin-13 (IL-13) — known to trigger skin issues.

A monoclonal antibody, dupilumab, targets the IL-4Ra receptors, blocking the signaling of IL-4 and IL-13. Study: Dupilumab use is associated with protection from COVID-19 mortality: A ...

"Dupilumab is known to make AD better and theoretically could help MF via its effect on interleukin (IL)–13, yet case reports of exacerbation and/or unmasking of MF are out there." ...